UCB FILES NDA FOR LACOSAMIDE FOR DIABETIC NEUROPATHIC PAIN

摘要

UCB has announced that the FDA has accepted for filing the New Drug Application (NDA) for the use of lacosamide in the treatment of diabetic neuropathic pain.The application relates to the tablet formulation of lacosamide,whose proposed trade name is Vimpat(tm).